《BioRxiv，5月8日，The transcriptomic profiling of COVID-19 compared to SARS, MERS, Ebola, and H1N1》

• 来源专题：COVID-19科研动态监测
• 编译者： zhangmin
• 发布时间：2020-05-10
• 原文来源：https://www.biorxiv.org/content/10.1101/2020.05.06.080960v1

The transcriptomic profiling of COVID-19 compared to SARS, MERS, Ebola, and H1N1

View ORCID ProfileAlsamman M Alsamman, View ORCID ProfileHatem Zayed

doi: https://doi.org/10.1101/2020.05.06.080960

Abstract

COVID-19 pandemic is a global crisis that threatens our way of life. As of April 29, 2020, COVID-19 has claimed more than 200,000 lives, with a global mortality rate of ~7% and recovery rate of ~30%. Understanding the interaction of cellular targets to the SARS-CoV2 infection is crucial for therapeutic development. Therefore, the aim of this study was to perform a comparative analysis of transcriptomic signatures of infection of COVID-19 compared to different respiratory viruses (Ebola, H1N1, MERS-CoV, and SARS-CoV), to determine unique anti-COVID1-19 gene signature. We identified for the first time molecular pathways for Heparin-binding, RAGE, miRNA, and PLA2 inhibitors, to be associated with SARS-CoV2 infection. The NRCAM and SAA2 that are involved in severe inflammatory response, and FGF1 and FOXO1genes, which are associated with immune regulation, were found to be associated with a cellular gene response to COVID-19 infection.

*注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.